A $1.1-million NSF grant awarded to Advanced Polymer Monitoring Technologies will be used for the development of a characterization technology for monitoring aggregation in biopharmaceuticals.
With the help of a $1.1-million grant through the National Science Foundation’s (NSF’s) Small Business Innovation Research program, Advanced Polymer Monitoring Technologies (APMT) announced it will develop a multiple-sample light-scattering technology to characterize biomolecules. Specifically, the technology will measure the stability of biopharmaceuticals and will provide information about if there is any protein aggregation occurring in samples.
The technology, known as the Aggregation Rate Generator (ARGEN) product, measures degradation “under computer-controlled thermal, mechanical, and chemical stimulus,” according to a company press release. ARGEN’s patented system incorporates proprietary hardware with analytics software. The platform facilitates early detection of aggregation and high-throughput formulation stability testing, and is capable of running 16 independent experiments simultaneously. The tool can help investigators determine the actual rate of aggregation through continuous monitoring of the aggregation process, as opposed to just providing aggregation information before and after the aggregation event.
Source: APMT press release
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
August 5th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.